Clinical Trials Logo

Filter by:
NCT ID: NCT02514681 Active, not recruiting - Clinical trials for HER2-positive Locally Advanced or Metastatic Breast Cancer

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

PRECIOUS
Start date: August 1, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer patients for previously treated with pertuzumab

NCT ID: NCT02514603 Completed - Neoplasm Clinical Trials

A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

Start date: October 2015
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.

NCT ID: NCT02513732 Completed - Clinical trials for Coronary Artery Disease

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)

Start date: July 2014
Phase:
Study type: Observational

The objective of the study is to evaluate the safety and efficacy of XIENCE Xpedition Everolimus-Eluting 2.25mm Stent in real world practice in Japanese hospitals.

NCT ID: NCT02513719 Completed - Clinical trials for Coronary Artery Disease

XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)

Start date: May 13, 2013
Phase:
Study type: Observational

The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real world practice in Japanese hospitals.

NCT ID: NCT02513550 Completed - Plaque Psoriasis Clinical Trials

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

IXORA-P
Start date: August 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

NCT ID: NCT02513394 Active, not recruiting - Breast Cancer Clinical Trials

PALbociclib CoLlaborative Adjuvant Study

PALLAS
Start date: August 2015
Phase: Phase 3
Study type: Interventional

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.

NCT ID: NCT02512068 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

Start date: August 7, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly using placebo as a control in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal disease and inadequate glycemic control despite diet and/or exercise therapy (if given) or despite treatment with one antidiabetic drug in addition to diet and/or exercise therapy (if given); and to evaluate the long-term efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly to patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal disease.

NCT ID: NCT02511106 Active, not recruiting - Clinical trials for Stage IB-IIIA Non-small Cell Lung Carcinoma

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

ADAURA
Start date: October 21, 2015
Phase: Phase 3
Study type: Interventional

To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

NCT ID: NCT02510274 Completed - Clinical trials for Chronic Kidney Disease

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

Start date: May 12, 2014
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal

NCT ID: NCT02510261 Completed - Amyloidosis Clinical Trials

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Start date: July 16, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).